Key results from a review of the abuse potential of lemborexant in patients with insomnia: a plain language summary
Notice bibliographique
Résumé
Plain Language SummaryWhat is this summary about?Lemborexant is medication prescribed for the treatment of insomnia, a disorder where people have trouble falling asleep and/or staying asleep. Lemborexant is a type of medication called a dual orexin-receptor antagonist (DORA). Since lemborexant acts on the central nervous system, it is important to understand whether there is potential for abuse. Abuse potential can be assessed using the United States Controlled Substances Act ‘8-factor analysis’. This review discusses what is known about lemborexant according to each of the 8 factors.What did the researchers find?Lemborexant did not show risk of abuse in nonclinical (animal) testing, but did show risk of abuse in a human abuse potential study. Like other similar medications (other DORAs like suvorexant and daridorexant), people who use sedatives recreationally found lemborexant to be ‘likeable’. However, internet surveillance suggests that DORA drugs have very low abuse-related risks in the community. Further, lemborexant did not produce withdrawal symptoms in phase 3 clinical trials, had no abuse-related side effects (such as euphoria) with approved doses, provided significant benefits on sleep, and didn’t cause next-morning effects (lingering feelings or side effects the morning after taking a sleep medication).What do the findings mean?Like most prescription insomnia medications, lemborexant was placed into Schedule IV as a controlled substance. However, the collective evidence described here suggests that DORAs, including lemborexant, may be less likely to be abused in the real world, thereby having lower risks to public health, than sedative-hypnotic drugs. If ongoing postmarketing data (ongoing since the time of the article’s original publication in February 2023) demonstrate that lemborexant is associated with lower rates of abuse than other Schedule IV hypnotics, then reducing lemborexant to a Schedule V substance or removing the scheduling of lemborexant altogether may be in the interest of public safety.How to say (download PDF and double click sound icon to play sound)…Lemborexant: lem-bow-rex-antInternet surveillance: The monitoring and collecting of information about an individual’s online activity. In this study, internet surveillance refers to information collected from individuals on popular online forums frequented by users of recreational drugs.Phase 3 clinical trial: A clinical study conducted in humans that tests how safe and how well a new medicine works compared with a standard treatment.Sedative-hypnotic: A medicine that slows down brain activity, leading to sedation (i.e., a calming effect) or inducing sleep (i.e., hypnotic)Schedule IV: Substances in this category have a lower potential for abuse compared with substances in the Schedule III category; however, despite their lower abuse potential, Schedule IV substances still carry a potential risk for physical or psychological dependence.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-textLink to original article here
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,002 | 0,000 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,001 | 0,000 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».